A Randomized, Multi-Center, Investigator-Masked, Parallel Group, Equivalence Study of Once Daily Brimonidine Tartrate Ophthalmic Suspension Compared With Three Times Daily ALPHAGAN-P® in Subjects With Open Angle Glaucoma, or Ocular Hypertension
Phase of Trial: Phase III
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Brimonidine (Primary) ; Brimonidine (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Sun Pharma Advanced Research Company
- 16 Jul 2019 Planned End Date changed from 1 Oct 2019 to 1 Apr 2020.
- 16 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
- 07 Feb 2019 Planned End Date changed from 1 Jun 2019 to 1 Oct 2019.